anti-DLL-4 mAb (Boston Children's Hospital/Seattle Children's Hosp/Harvard Med School/Regeneron Pharm/Univ Minnesota/Univ Pittsburgh)

N/A

Report date: 2025/03/14 16:35:07

Base Information

Drug Nameanti-DLL-4 mAb (Boston Children's Hospital/Seattle Children's Hosp/Harvard Med School/Regeneron Pharm/Univ Minnesota/Univ Pittsburgh)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionDelta-like protein 4 inhibitors
TargetsDelta-like protein 4
Therapy Area/IndicationsGraft vs Host Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRegeneron Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesThe Children's Hospital CorpUniversity Of MinnesotaHarvard Medical School +[6] 
Inactive CompaniesN/A
Active IndicationsGraft vs Host Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A